BioScrip Inc (NASDAQ:BIOS) shares shot up 4.9% during mid-day trading on Wednesday . The stock traded as high as $2.89 and last traded at $3.01. 527,392 shares were traded during mid-day trading, a decline of 40% from the average session volume of 872,416 shares. The stock had previously closed at $2.87.

Several research firms have recently issued reports on BIOS. BidaskClub cut shares of BioScrip from a “buy” rating to a “hold” rating in a report on Friday, January 26th. Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. SunTrust Banks set a $4.00 target price on shares of BioScrip and gave the company a “buy” rating in a research note on Thursday, December 21st. Finally, ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a research note on Thursday, November 30th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $3.63.

The company has a market cap of $386.37, a P/E ratio of -4.89 and a beta of 0.19. The company has a current ratio of 1.91, a quick ratio of 1.60 and a debt-to-equity ratio of -6.11.

BioScrip (NASDAQ:BIOS) last released its earnings results on Thursday, November 2nd. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The company had revenue of $198.70 million for the quarter, compared to analyst estimates of $202.91 million. During the same period in the previous year, the company posted ($0.12) earnings per share. BioScrip’s revenue was down 11.5% on a year-over-year basis. equities analysts predict that BioScrip Inc will post -0.63 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. lifted its position in shares of BioScrip by 0.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 490,698 shares of the company’s stock valued at $1,333,000 after acquiring an additional 2,622 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of BioScrip by 6.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 504,459 shares of the company’s stock valued at $1,369,000 after acquiring an additional 28,615 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of BioScrip by 1.0% in the 2nd quarter. Wells Fargo & Company MN now owns 114,810 shares of the company’s stock valued at $312,000 after acquiring an additional 1,100 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of BioScrip by 50.8% in the 2nd quarter. Alliancebernstein L.P. now owns 141,900 shares of the company’s stock valued at $385,000 after acquiring an additional 47,800 shares in the last quarter. Finally, Teachers Advisors LLC lifted its position in shares of BioScrip by 10.2% in the 2nd quarter. Teachers Advisors LLC now owns 219,040 shares of the company’s stock valued at $595,000 after acquiring an additional 20,290 shares in the last quarter. 84.53% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2018/02/08/bioscrip-bios-shares-up-4-9.html.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.